Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves ...
Jul 2, 2018
0
2